Kwality Pharmaceuticals Limited (KPL) Fair Value & Analysis
Healthcare · IN · Market cap ₹27.8B
Fair value as of: Jul 5, 2026
From 14 valuation models · updated today
Share price +14.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹838.20 – ₹2,802 · fair‑value band ₹777.57 – ₹1,623 · the ₹2,676 price screens above the ₹1,111 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Kwality Pharmaceuticals Limited (KPL) currently trades at ₹2,676, while our model-based Fair Value estimate is ₹1,111 — implying the stock looks roughly 58.5% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Kwality Pharmaceuticals Limited generated revenue of ₹5.0B at a net margin of 13.4%. Revenue grew 35.8% year over year. It earns a return on equity of 22.7%. Net debt stands at ₹1.3B. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹777.57 (bear case) to ₹1,623 (bull case); at ₹2,676, the current price sits above that range. The share trades about 7% below its 52-week high and 223% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside — at -58%, KPL screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures, buys, sells, and deals finished pharmaceutical formulations in India and internationally. It offers its products in various dosage forms, including liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments/cream, external preparations, ORS, eye/ear drops, sanitizers, suppositories, injectable vials and ampoules, lyophilized and covid products, syrups, daunorubicin, and other various categories, such as Beta Lactam, non-Beta Lactam, hormones, cytotoxic (oncology), and effervescent. The company also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations. Kwality Pharmaceuticals Limited was incorporated in 1983 and is based in Amritsar, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kwality Pharmaceuticals Limited reported revenue of ₹5.0B in FY2025 versus ₹6.3B in FY2021, a compound −5.3%/yr. Reported net income was ₹673M in FY2025, compounding +26.6%/yr from FY2021.
Is KPL fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kwality Pharmaceuticals Limited (KPL) undervalued?
What is the fair value of KPL?
What is the quality score of KPL?
What is the revenue of Kwality Pharmaceuticals Limited (KPL)?
What is the net profit margin of KPL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.